In vivo administrations of anti‐Lyt‐2.2 (CDS) mAb and anti‐L3T4 (CD4) mAb selectively eliminated CD8+ cells amd CD4+ cells, respectively. The relative potencies of CD8+ cells and CD4+ cells and their roles in primary tumor rejections were studied by investigating the effects of these mAbs on tumor growth. CD8+ cells were themselves fully capable of mediating rejection in 5 different tumor rejection systems: two radiation leukemia virus (RadLV)‐induced leukemias, B6RV2 and BALBRVD, a radiation‐induced leukemia BALBRL♂1, and a plasmacytoma BALBMOPC‐70A in CB6F1 mice, and a Friend virus‐induced leukemia B6FBL‐3 in B6 mice. On the other hand, CD4+ cells were capable of resisting tumor growth of B6FBL‐3, but not of the other four tumors. Furthermore, for efficient rejection of CB6F1UV+˚l sarcoma by CB6F1 mice, synergy of CDS+ and CD4+ cells was necessary. Blocking of UV+˚ 1 rejection was abrogated by delayed administration of anti‐L3T4 (CD4) mAb but not anti‐Lyt‐2.2 (CDS) mAb, indicating the involvement of CD4+ cells in only the initial phase of rejection.
|Number of pages||6|
|Journal||Japanese Journal of Cancer Research|
|Publication status||Published - Jul 1989|
- Tumor rejection
- T‐cell subsets
ASJC Scopus subject areas
- Cancer Research